Accretion Pharmaceuticals Management

Management criteria checks 1/4

Accretion Pharmaceuticals' CEO is Vivek Ashok Patel, appointed in Jul 2024, has a tenure of less than a year. directly owns 18.37% of the company’s shares, worth ₹152.98M. The average tenure of the management team and the board of directors is 0.8 years and 1.5 years respectively.

Key information

Vivek Ashok Patel

Chief executive officer

₹1.6m

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	18.4%
Management average tenure	less than a year
Board average tenure	1.5yrs

Recent management updates

Recent updates

CEO

Vivek Ashok Patel (37 yo)

less than a year

Tenure

₹1,598,000

Compensation

Mr. Vivek Ashok Kumar Patel is MD of Accretion Pharmaceuticals Limited from July 9, 2024 and serves as its Director since November 20, 2023. He has completed his MBA in Pharma from DY Patil Institute in Mu...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Harshadbhai Rathod	CFO & Executive Chairman	1.5yrs	₹1.60m	18.37% ₹ 153.0m
Vivek Ashok Patel	MD & Director	less than a year	₹1.60m	18.37% ₹ 153.0m
Bhavika Makadia	Company Secretary & Compliance Officer	less than a year	₹553.32k	no data
Mayurbhai Sojitra	Executive Non Independent Director	1.5yrs	₹1.60m	18.37% ₹ 153.0m
Hardik Prajapati	Executive Director	1.5yrs	₹1.60m	18.37% ₹ 153.0m

0.8yrs

Average Tenure

37yo

Average Age

Experienced Management: ACCPL's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Harshadbhai Rathod	CFO & Executive Chairman	1.5yrs	₹1.60m	18.37% ₹ 153.0m
Vivek Ashok Patel	MD & Director	1.5yrs	₹1.60m	18.37% ₹ 153.0m
Mayurbhai Sojitra	Executive Non Independent Director	1.5yrs	₹1.60m	18.37% ₹ 153.0m
Hardik Prajapati	Executive Director	1.5yrs	₹1.60m	18.37% ₹ 153.0m
Vijay Anadkat	Non-Executive Independent Director	less than a year	₹103.50k	no data
Grishma Shewale	Independent Non-Executive Women Director	less than a year	₹94.50k	no data
Chand Kanabar	Non-Executive Independent Director	less than a year	no data	no data

1.5yrs

Average Tenure

37yo

Average Age

Experienced Board: ACCPL's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/25 23:14
End of Day Share Price	2025/05/23 00:00
Earnings	2024/03/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Accretion Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.